These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26188358)

  • 21. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage.
    Minn AJ; Boise LH; Thompson CB
    Genes Dev; 1996 Oct; 10(20):2621-31. PubMed ID: 8895663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
    Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
    Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of Bcl-xL-ATP Synthase Interaction by Mitochondrial Cyclin B1-Cyclin-Dependent Kinase-1 Determines Neuronal Survival.
    Veas-Pérez de Tudela M; Delgado-Esteban M; Maestre C; Bobo-Jiménez V; Jiménez-Blasco D; Vecino R; Bolaños JP; Almeida A
    J Neurosci; 2015 Jun; 35(25):9287-301. PubMed ID: 26109654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.
    Castellanet O; Ahmad F; Vinik Y; Mills GB; Habermann B; Borg JP; Lev S; Lamballe F; Maina F
    Theranostics; 2021; 11(19):9180-9197. PubMed ID: 34646365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDK1 switches mitotic arrest to apoptosis by phosphorylating Bcl-2/Bax family proteins during treatment with microtubule interfering agents.
    Zhou L; Cai X; Han X; Xu N; Chang DC
    Cell Biol Int; 2014 Jun; 38(6):737-46. PubMed ID: 24677263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL.
    Jeong NY; Yoon YG; Rho JH; Lee JS; Lee SY; Yoo KS; Song S; Suh H; Choi YH; Yoo YH
    Int J Oncol; 2011 Jun; 38(6):1597-604. PubMed ID: 21424121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.
    Chang LC; Yu YL; Liu CY; Cheng YY; Chou RH; Hsieh MT; Lin HY; Hung HY; Huang LJ; Wu YC; Kuo SC
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1303-15. PubMed ID: 25947085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
    Liu LL; Long ZJ; Wang LX; Zheng FM; Fang ZG; Yan M; Xu DF; Chen JJ; Wang SW; Lin DJ; Liu Q
    Mol Cancer Res; 2013 Nov; 11(11):1326-36. PubMed ID: 24008673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPG6 supports development of acute myeloid leukemia by regulating BMPR2-Smad-Bcl-2/Bcl-xl signaling.
    Chen J; Li C; Zhan R; Yin Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):220-225. PubMed ID: 29715457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.
    Terrano DT; Upreti M; Chambers TC
    Mol Cell Biol; 2010 Feb; 30(3):640-56. PubMed ID: 19917720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
    Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
    Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
    Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
    Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
    Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
    BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
    Guo J; Roberts L; Chen Z; Merta PJ; Glaser KB; Shah OJ
    PLoS One; 2015; 10(3):e0114363. PubMed ID: 25781882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.